These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37195314)

  • 21. Clinical utility of vesical imaging-reporting and data system (VI-RADS) in non-muscle invasive bladder cancer (NMIBC) patients candidate for en-bloc transurethral resection: A prospective study.
    El-Karamany TM; Al-Adl AM; Hosny MM; A Eldeep H; El-Hamshary SA
    Urol Oncol; 2022 Oct; 40(10):454.e1-454.e7. PubMed ID: 35466036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carcinoma in situ of the urinary bladder - from pathology to narrow band imaging.
    Geavlete BF; Brînzea A; ChecheriŢă IA; Zurac SA; Georgescu DA; Bastian AE; Ene CV; Bulai CA; Geavlete DO; Zaharia MR; Geavlete PA
    Rom J Morphol Embryol; 2015; 56(3):1069-76. PubMed ID: 26662141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New optical imaging technologies for bladder cancer: considerations and perspectives.
    Liu JJ; Droller MJ; Liao JC
    J Urol; 2012 Aug; 188(2):361-8. PubMed ID: 22698620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy.
    Kufukihara R; Kikuchi E; Shigeta K; Ogihara K; Arita Y; Akita H; Suzuki T; Abe T; Mizuno R; Jinzaki M; Oya M
    Urol Oncol; 2022 Feb; 40(2):61.e1-61.e8. PubMed ID: 34332846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer.
    Erkoc M; Otunctemur A; Bozkurt M; Can O; Atalay HA; Besiroglu H; Danis E; Degirmentepe RB
    Int J Clin Pract; 2021 Sep; 75(9):e14584. PubMed ID: 34185372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
    Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
    Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bladder cancer local staging: multiparametric MRI performance following transurethral resection.
    van der Pol CB; Shinagare AB; Tirumani SH; Preston MA; Vangel MG; Silverman SG
    Abdom Radiol (NY); 2018 Sep; 43(9):2412-2423. PubMed ID: 29313114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
    Fukuhara H; Yamamoto S; Lai HW; Karashima T; Kurabayashi A; Furihata M; Inoue K
    Photodiagnosis Photodyn Ther; 2022 Jun; 38():102757. PubMed ID: 35151889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial transurethral resection for non-muscle-invasive bladder cancer under white light cystoscopy.
    Iinuma K; Yuhara K; Kotaka H; Ozawa K; Kato D; Takai M; Nakane K; Mizutani K; Tsuchiya T; Koie T
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1321. PubMed ID: 33174397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
    Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
    BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
    Herr HW
    Eur Urol; 2015 Apr; 67(4):605-8. PubMed ID: 25041849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.
    Nakai Y; Inoue K; Tsuzuki T; Shimamoto T; Shuin T; Nagao K; Matsuyama H; Oyama M; Furuse H; Ozono S; Miyake M; Fujimoto K
    Int J Urol; 2018 Aug; 25(8):723-729. PubMed ID: 29999205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters?
    Shen YJ; Zhu YP; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Zhu Y
    Int Urol Nephrol; 2012 Apr; 44(2):451-7. PubMed ID: 21792663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.